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can be adopted, based on the result of 
rebiopsy.
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Our present case has shown spa-
tiotemporal T790M heterogeneity in an 
individual patient with EGFR-mutant 
non–small-cell lung cancer. One year after 
gefitinib-free interval, T790M status was 
distinct between the primary tumor and 
the metastatic nodule. T790M is medi-
ated by tyrosine kinase inhibitor (TKI)-
exposure, and TKI-withdrawal reduces 
the proportion of T790M-harboring cells 
in an EGFR-mutant tumor.2 T790M-
negative cancer cells might have grown 
in the metastatic nodule during gefi-
tinib withdrawal. Interestingly, both the 
primary tumor and metastatic nodules 
responded to gefitinib. It is natural that 
the T790M-negative metastatic nodules 
responded to gefitinib, but it is curious 
that T790M-positive primary tumor also 
responded. In preclinical data, erlotinib 
sensitivity decreases as T790M-positive 
cancer cells occupy from 10 to 25% in a 
mixed population of sensitive and resis-
tant cells.2 Tumors harboring low levels 
of T790M can still respond to EGFR-
TKI.3 A highly sensitive polymerase 
chain reaction method could detect a 
small portion (<10–25%) of T790M-
positive cells in the primary tumor.
T790M status is spatiotempo-
rally heterogeneous because of selec-
tive pressure from TKI. Local ablative 
therapies and EGFR-TKI rechallenge 
FIGURE 1.  Chest computed tomog-
raphy (CT) before gefitinib therapy: 
(A) T790M-positive primary tumor 
(arrow) and (B) T790M-negative 
pulmonary metastasis (arrow-
head). Chest CT 2 months later: 
(C) the responding primary tumor 
(arrow) and (D) metastatic nodule 
(arrowhead).
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Larger Studies of 
Multiple Families 
Will Help Us Better 
Understand Inherited 
Risk of Lung Cancer
To the Editor:
As a lung cancer survivor, pas-
sionate advocate for lung cancer 
patients around the world and founder 
of two lung cancer foundations—
the Bonnie J. Addario Lung Cancer 
Foundation and the Addario Lung 
Cancer Medical Institute (ALCMI)—I 
would like to respond to and commend 
Dr. David Carbone’s editorial in the 
Journal of Thoracic Oncology (An era 
of lung cancer iconoclasts. 2014:9). Dr. 
Carbone highlights the opportunities 
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and challenges of emerging data on 
germline mutations in the epidermal 
growth factor receptor (EGFR) gene in 
cases of familial lung adenocarcinoma, 
an exciting development for lung can-
cer patients and, possibly, as signifi-
cant a discovery in lung cancer as the 
BRCA gene mutations were to breast 
cancer. Two reports in the same issue of 
Journal of Thoracic Oncology highlight 
findings from studies on two families 
that presented with the inherited muta-
tion in EGFR and a 31% increased risk 
for lung cancer, seen higher in mutation 
carriers with no history of smoking. 
These studies clearly demonstrate that a 
family history of inherited mutations in 
the EGFR gene plays an important role 
in the initiation and progression of lung 
cancer, but we still do not understand the 
hows and whys behind this association. 
Besides, these two Journal of Thoracic 
Oncology studies, though significant, 
are small and focus on single families. 
To better understand the inherited risk 
of lung cancer, we need larger studies 
that study multiple families under a col-
laborative paradigm. 
To this end, the Bonnie J. Addario 
Lung Cancer Foundation and ALCMI 
have funded, developed and launched a 
prospective multifamily, national study 
called Investigating Hereditary Risk 
from the T790M mutation in EGFR 
(INHERIT). Our goal is to better under-
stand the underlying biology of lung 
cancer and help us determine whether 
having this inherited gene alteration 
raises the risk of familial lung cancer 
in patients and family members. It is 
our hope that this study will provide 
insight into why lung cancer develops, 
determine whether inherited factors 
may partly explain the disease in indi-
viduals without apparent carcinogenic 
association (otherwise known as never 
smokers), and ultimately expedite and 
advance treatment for those presenting 
with the T790M mutation in the EGFR 
gene.
Under the direction of Geoffrey 
Oxnard, MD of the Dana-Farber Cancer 
Institute , the INHERIT study to date 
has enrolled 29 (of 100 targeted) 
subjects from 14 different families. 
Currently, INHERIT is open at two 
ALCMI member institutions—Dana-
Farber Cancer Institute and Vanderbilt 
University—and will soon open at The 
Ohio State University. Importantly, 
subjects can also enroll and partici-
pate remotely through a study website 
(www.dana-farber.org/T790Mstudy/).
On a personal note, lung cancer 
is well known in my family having 
claimed the lives of my mother, mater-
nal aunt, maternal uncle, and grandfa-
ther. And 10 years ago, I was personally 
diagnosed with stage IIIB lung cancer. 
I was incredibly encouraged that within 
weeks of INHERIT's launch, a pres-
ymptomatic, first-degree relative of a 
lung cancer patient was diagnosed and 
treated, having a 0.8 cm adenocarci-
noma in situ removed with clear mar-
gins and no lymph node involvement. 
This was a direct result of her mother 
undergoing germline testing and the 
resultant screening of her family mem-
bers for germline T790M. In his edi-
torial, Dr. Carbone commented on the 
lack of data defining how to manage 
and advise such carriers of germline 
T790M. The success of INHERIT and 
similar studies will be fundamental to 
addressing this key gap. 
The present and future of all can-
cer treatment and care, particularly lung 
cancer, and other so-called recalcitrant 
cancers, resides in tailored approaches 
driven by genetic testing and targeted 
treatment based on the results of that 
testing. If INHERIT can show that an 
inherited gene mutation raises the risk 
of lung cancer in certain families—
especially in never-smoking families—
what else might we learn about lung 
cancer through genetic testing?
Further, identification of these 
inherited mutations in lung cancer 
patients clearly points to the fact that 
this patient subtype will respond dif-
ferently to traditional, first-generation 
EGFR tyrosine kinase inhibitors, high-
lighting the need for new, targeted ther-
apeutic agents for these patients.
In closing, we call for all lung 
cancer patients to be offered molecular 
testing of their tumors and, as feasible, 
targeted therapies under the precision 
medicine paradigm. We do not know 
enough about lung cancer yet to trans-
form it into a chronically managed 
illness, but I do know that informed 
patients (and physicians) clearly have 
better outcomes. Hope is on the hori-
zon, and we could not be more proud 
to be working in collaboration with the 
brightest minds to help drive research 
and discovery efforts around the globe. 
We constantly remind ourselves: if it 
is good for patients, then the answer 
is easy—and this work is good for 
patients.
Bonnie J. Addario
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San Carlos, CA
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